Unknown

Dataset Information

0

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.


ABSTRACT: Development of tau-based therapies for Alzheimer's disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer's disease. We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time. These tau phosphorylation state changes are uniquely associated with structural, metabolic, neurodegenerative and clinical markers of disease, and some (p-tau217 and p-tau181) begin with the initial increases in aggregate amyloid-? as early as two decades before the development of aggregated tau pathology. Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to symptom onset. These findings provide insights into the pathways linking tau, amyloid-? and neurodegeneration, and may facilitate clinical trials of tau-based treatments.

SUBMITTER: Barthelemy NR 

PROVIDER: S-EPMC7309367 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.

Barthélemy Nicolas R NR   Li Yan Y   Joseph-Mathurin Nelly N   Gordon Brian A BA   Hassenstab Jason J   Benzinger Tammie L S TLS   Buckles Virginia V   Fagan Anne M AM   Perrin Richard J RJ   Goate Alison M AM   Morris John C JC   Karch Celeste M CM   Xiong Chengjie C   Allegri Ricardo R   Mendez Patricio Chrem PC   Berman Sarah B SB   Ikeuchi Takeshi T   Mori Hiroshi H   Shimada Hiroyuki H   Shoji Mikio M   Suzuki Kazushi K   Noble James J   Farlow Martin M   Chhatwal Jasmeer J   Graff-Radford Neill R NR   Salloway Stephen S   Schofield Peter R PR   Masters Colin L CL   Martins Ralph N RN   O'Connor Antoinette A   Fox Nick C NC   Levin Johannes J   Jucker Mathias M   Gabelle Audrey A   Lehmann Sylvain S   Sato Chihiro C   Bateman Randall J RJ   McDade Eric E  

Nature medicine 20200311 3


Development of tau-based therapies for Alzheimer's disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer's disease. We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over  ...[more]

Similar Datasets

| S-EPMC6309096 | biostudies-literature
| S-EPMC5942789 | biostudies-literature
| S-EPMC5385711 | biostudies-literature
| S-EPMC3474597 | biostudies-literature
| S-EPMC5920320 | biostudies-literature
| S-EPMC8590691 | biostudies-literature
| S-EPMC6153076 | biostudies-literature
| S-EPMC8988051 | biostudies-literature
| S-EPMC7159908 | biostudies-literature
| S-EPMC6151331 | biostudies-literature